Walmart Joins Nasdaq-100, Replacing AstraZeneca in Major Index Reshuffle Starting January 2026

ser_ngmi · 2026-01-12T17:32:21+00:00

Walmart Inc. will join the Nasdaq-100 Index and related indices in January 2026, marking its elevated market status, while AstraZeneca will be removed. This reshuffle will impact investors and fund compositions, highlighting changes in sector dynamics.

ser_ngmi

2026-01-12 17:32:21

Abstract generation in progress

WMT Ascends to Elite Index Club

Nasdaq has confirmed a significant index reshuffle set to reshape its benchmark holdings. Walmart Inc. (WMT) is stepping in to join the Nasdaq-100 Index (NDX), alongside the Nasdaq-100 Equal Weighted Index (NDXE) and the Nasdaq-100 Ex-Tech Sector Index (NDXX) as of January 20, 2026. The shift marks a notable milestone for the retail giant, signaling its elevated status in the market.

AstraZeneca Makes Room

Meanwhile, AstraZeneca PLC (AZN) is being removed from these key indices. The pharmaceutical giant’s exit isn’t limited to just the primary Nasdaq-100 Index—it will also be pruned from multiple specialized indices including the Nasdaq-100 ESG Index (NDXESG), Nasdaq-100 ex Top 30 (NDX70), Nasdaq-100 ex Top 30 UCITS (NDX70U), Nasdaq-100 Sustainable ESG Select (NDXSES), Nasdaq-100 Low Volatility (NDXLV), and Nasdaq-100 Select Equal Weight (NDXSE).

What This Means for Investors

The index reconstruction takes effect prior to market open on Tuesday, January 20, 2026—the first trading day following the third Friday of the month. For portfolio managers tracking these indices, this reshuffle will trigger rebalancing activities, potentially affecting fund composition and sector exposure. Walmart’s inclusion reinforces the retail sector’s prominence in the benchmark, while AstraZeneca’s broader removal could indicate shifting dynamics in pharmaceutical representation within Nasdaq’s elite equity baskets.

This index adjustment reflects the evolving landscape of large-cap equities and strategic positioning within institutional investment frameworks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.